Figures & data
Figure 1 Oxymorphone: structure similar to morphine and thebaine.
Figure 2 Mean single-dose and steady-state (q6 h dosing) plasma concentrations of oxymorphone IR (5, 10, and 20 mg doses) in healthy volunteers. Reprinted with permission from Adams MP, Ahdieh H. 2005. Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs R D, 6:91–9. Copyright © 2005 Lippincott Williams and Wilkins.
Figure 3 Mean steady-state plasma concentrations of oxymorphone ER over the 12-hour dosing interval in healthy volunteers. Reprinted with permission from Adams MP, Ahdieh H. 2004. Pharmacokinetics and dose-proportionality of oxymorphone ER and its metabolites: results of a randomized crossover study. Pharmacotherapy, 24:468–76. Copyright © 2004 Pharmacotherapy Publications.
Figure 4 Mean (SEM) visual analog scale daily pain scores (0 = no pain, 10 = worst pain) for all cancer patients receiving MS Contin® (morphine sulfate), OxyContin® (oxycodone continuous release), and oxymorphone ER.
Figure 5 Mean (SEM) opioid daily dose for all cancer patients receiving MS Contin® (morphine sulfate), OxyContin® (oxycodone continuous release), and oxymorphone ER.
Figure 6 Mean current visual analog scale pain intensity (0 = no pain; 100 = worst pain) over a one-year clinical trial of oxymorphone ER for arthritis pain. (The number of patients included in scoring is given above the error bar for each assessment) Reprinted with permission from McIlwain H, Ahdieh H. 2005. Safety, tolerability, and effectiveness of oxymorphone extended-release for moderate to severe osteoarthritis pain: a one-year study. Am J Ther, 12:106–12. Copyright © Lippincott Williams and Wilkins.
